SG11201401386XA - Treatment of hematologic malignancies with an anti-cxcr4 antibody - Google Patents
Treatment of hematologic malignancies with an anti-cxcr4 antibodyInfo
- Publication number
- SG11201401386XA SG11201401386XA SG11201401386XA SG11201401386XA SG11201401386XA SG 11201401386X A SG11201401386X A SG 11201401386XA SG 11201401386X A SG11201401386X A SG 11201401386XA SG 11201401386X A SG11201401386X A SG 11201401386XA SG 11201401386X A SG11201401386X A SG 11201401386XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hematologic malignancies
- cxcr4 antibody
- cxcr4
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557815P | 2011-11-09 | 2011-11-09 | |
| US201161569113P | 2011-12-09 | 2011-12-09 | |
| PCT/US2012/064395 WO2013071068A2 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401386XA true SG11201401386XA (en) | 2014-10-30 |
Family
ID=47179025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401386XA SG11201401386XA (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10428151B2 (en) |
| EP (1) | EP2776032B1 (en) |
| JP (1) | JP6541350B2 (en) |
| KR (1) | KR102024957B1 (en) |
| CN (1) | CN104039320B (en) |
| AU (1) | AU2012335553B2 (en) |
| BR (1) | BR112014011144A2 (en) |
| CA (1) | CA2855155A1 (en) |
| CY (1) | CY1121331T1 (en) |
| DK (1) | DK2776032T3 (en) |
| EA (1) | EA026153B1 (en) |
| ES (1) | ES2705001T3 (en) |
| HR (1) | HRP20182183T1 (en) |
| HU (1) | HUE043001T2 (en) |
| IL (1) | IL232517B (en) |
| LT (1) | LT2776032T (en) |
| MX (1) | MX357100B (en) |
| PL (1) | PL2776032T3 (en) |
| PT (1) | PT2776032T (en) |
| RS (1) | RS58102B1 (en) |
| SG (1) | SG11201401386XA (en) |
| SI (1) | SI2776032T1 (en) |
| WO (1) | WO2013071068A2 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450464B2 (en) * | 2006-10-02 | 2013-05-28 | Medarex, Inc. | Human monoclonal antibodies that bind CXCR4 |
| EP2726634B1 (en) | 2011-07-01 | 2017-02-22 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
| WO2015019284A2 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| AU2014318614B2 (en) | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
| JP6837837B2 (en) * | 2013-11-06 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Treatment of C1013G / CXCR4-related Waldenström macroglobulinemia with anti-CXCR4 antibody |
| US10612095B2 (en) | 2013-12-06 | 2020-04-07 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
| KR20240042192A (en) | 2013-12-17 | 2024-04-01 | 크링 바이오테라퓨틱스 비.브이. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
| WO2015118538A1 (en) | 2014-02-06 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
| EP3125919A4 (en) * | 2014-02-19 | 2018-01-03 | Microconstants China Inc. | Chemokine receptor antagonist and its combinational therapy |
| CN107427574B (en) * | 2015-01-09 | 2022-02-08 | 阿达尔塔有限公司 | CXCR4 binding molecules |
| HUE050894T2 (en) | 2015-04-17 | 2021-01-28 | Bristol Myers Squibb Co | Compositions comprising a combination of ipilimumab and nivolumab |
| WO2016201425A1 (en) | 2015-06-12 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| JP2018521983A (en) | 2015-07-16 | 2018-08-09 | バイオカイン セラピューティックス リミテッド | Compositions and methods for treating cancer |
| CA2999756A1 (en) * | 2015-09-24 | 2017-03-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| AU2016352910A1 (en) * | 2015-11-09 | 2018-05-31 | The General Hospital Corporation D.B.A Massachusetts General Hospital | Unit dose formulations for use as an anti-fugetactic agent |
| BR112018016924A2 (en) * | 2016-02-23 | 2019-01-02 | Biokine Therapeutics Ltd | treatment regimen selection method for individual who has acute myeloid leukemia (LMA), acute response myeloid leukemia (LMA) treatment maximization method, lma treatment method, cxcr4 antagonist, and chemotherapeutic agent in the treatment of lma |
| US10525060B2 (en) | 2016-04-29 | 2020-01-07 | Dana-Farber Cancer Institute, Inc. | HCK as a therapeutic target in MYD88 mutated diseases |
| MX2018013868A (en) | 2016-05-20 | 2019-02-21 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating agents with immunotherapies to treat cancer. |
| WO2017216368A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Compounds useful for decreasing interferon level |
| JP7461741B2 (en) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | Anti-PD-L1 and IL-2 Cytokines |
| JP2020508697A (en) * | 2017-01-31 | 2020-03-26 | エム・エス・エム・プロテイン・テクノロジーズ・インコーポレイテッド | Anti-CXCR4 antibody |
| TWI693074B (en) * | 2017-02-21 | 2020-05-11 | 美商庫拉腫瘤技術股份有限公司 | Methods of treating cancer with farnesyltransferase inhibitors |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20210162009A1 (en) * | 2017-12-08 | 2021-06-03 | The Medical College Of Wisconsin, Inc. | Chemokine variants as immune stimulants |
| CN112513079A (en) * | 2018-03-13 | 2021-03-16 | 拉巴斯大学医院生物医学研究基金会 | anti-CXCR4 antibodies for use in the combined activation and expansion of natural killer cells for cancer immunotherapy |
| PE20210665A1 (en) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES |
| WO2019191133A1 (en) | 2018-03-27 | 2019-10-03 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
| CN111971306A (en) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | Method for treating tumors |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| CN114245869A (en) | 2019-05-23 | 2022-03-25 | 百时美施贵宝公司 | Method for monitoring cell culture medium |
| US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| CA2117953C (en) | 1993-10-14 | 2001-12-11 | Tasuku Honjo | Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| ATE378403T1 (en) | 2000-11-30 | 2007-11-15 | Medarex Inc | TRANSCHROMOSOMAL TRANSGENIC RODENTS FOR PRODUCING HUMAN ANTIBODIES |
| US7674618B2 (en) | 2003-09-04 | 2010-03-09 | Medarex, Inc. | Expression vector |
| WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| ES2575518T3 (en) | 2006-02-28 | 2016-06-29 | Pharma Mar S.A. | Improved treatment of multiple myeloma |
| US8450464B2 (en) * | 2006-10-02 | 2013-05-28 | Medarex, Inc. | Human monoclonal antibodies that bind CXCR4 |
| FR2915102B1 (en) | 2007-04-23 | 2014-05-16 | Pf Medicament | USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER |
| MX2010012435A (en) | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anti-cxcr4 antibodies. |
| EP2352764B1 (en) | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| JP5709766B2 (en) * | 2009-03-12 | 2015-04-30 | ジェネンテック， インコーポレイテッド | Combination of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic tumors |
| TWI546537B (en) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| BR112013003823A2 (en) | 2010-08-20 | 2016-06-28 | Cerulean Pharma Inc | therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
-
2012
- 2012-11-09 LT LTEP12787343.8T patent/LT2776032T/en unknown
- 2012-11-09 WO PCT/US2012/064395 patent/WO2013071068A2/en active Application Filing
- 2012-11-09 AU AU2012335553A patent/AU2012335553B2/en not_active Ceased
- 2012-11-09 RS RS20181552A patent/RS58102B1/en unknown
- 2012-11-09 MX MX2014005267A patent/MX357100B/en active IP Right Grant
- 2012-11-09 BR BR112014011144A patent/BR112014011144A2/en not_active Application Discontinuation
- 2012-11-09 CA CA2855155A patent/CA2855155A1/en not_active Abandoned
- 2012-11-09 EP EP12787343.8A patent/EP2776032B1/en active Active
- 2012-11-09 DK DK12787343.8T patent/DK2776032T3/en active
- 2012-11-09 CN CN201280066551.7A patent/CN104039320B/en active Active
- 2012-11-09 EA EA201490957A patent/EA026153B1/en not_active IP Right Cessation
- 2012-11-09 JP JP2014541315A patent/JP6541350B2/en not_active Expired - Fee Related
- 2012-11-09 SG SG11201401386XA patent/SG11201401386XA/en unknown
- 2012-11-09 PT PT12787343T patent/PT2776032T/en unknown
- 2012-11-09 PL PL12787343T patent/PL2776032T3/en unknown
- 2012-11-09 KR KR1020147012396A patent/KR102024957B1/en active IP Right Grant
- 2012-11-09 ES ES12787343T patent/ES2705001T3/en active Active
- 2012-11-09 SI SI201231459T patent/SI2776032T1/en unknown
- 2012-11-09 HU HUE12787343A patent/HUE043001T2/en unknown
- 2012-11-09 US US14/356,996 patent/US10428151B2/en active Active
-
2014
- 2014-05-08 IL IL232517A patent/IL232517B/en active IP Right Grant
-
2018
- 2018-12-27 HR HRP20182183TT patent/HRP20182183T1/en unknown
-
2019
- 2019-01-15 CY CY20191100051T patent/CY1121331T1/en unknown
- 2019-10-01 US US16/590,152 patent/US20200231683A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102024957B1 (en) | 2019-09-24 |
| IL232517A0 (en) | 2014-06-30 |
| EA026153B1 (en) | 2017-03-31 |
| HUE043001T2 (en) | 2019-07-29 |
| JP2014533279A (en) | 2014-12-11 |
| MX357100B (en) | 2018-06-26 |
| AU2012335553A1 (en) | 2014-07-03 |
| SI2776032T1 (en) | 2018-12-31 |
| EA201490957A1 (en) | 2014-08-29 |
| DK2776032T3 (en) | 2019-02-04 |
| IL232517B (en) | 2018-05-31 |
| EP2776032B1 (en) | 2018-10-17 |
| CN104039320A (en) | 2014-09-10 |
| AU2012335553B2 (en) | 2017-09-21 |
| CN104039320B (en) | 2019-10-15 |
| ES2705001T3 (en) | 2019-03-21 |
| PL2776032T3 (en) | 2019-03-29 |
| PT2776032T (en) | 2019-01-21 |
| WO2013071068A2 (en) | 2013-05-16 |
| WO2013071068A3 (en) | 2013-07-18 |
| JP6541350B2 (en) | 2019-07-10 |
| HRP20182183T1 (en) | 2019-02-22 |
| RS58102B1 (en) | 2019-02-28 |
| US20140322208A1 (en) | 2014-10-30 |
| BR112014011144A2 (en) | 2017-05-16 |
| EP2776032A2 (en) | 2014-09-17 |
| US20200231683A1 (en) | 2020-07-23 |
| US10428151B2 (en) | 2019-10-01 |
| KR20140093945A (en) | 2014-07-29 |
| LT2776032T (en) | 2018-12-10 |
| CY1121331T1 (en) | 2020-05-29 |
| CA2855155A1 (en) | 2013-05-16 |
| MX2014005267A (en) | 2014-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20182183T1 (en) | Treatment of hematologic malignancies with an anti-cxcr4 antibody | |
| HK1255608A1 (en) | Anti-htra1 antibodies and methods of use | |
| IL228738A0 (en) | Antibodies for treatment of cancer | |
| EP2748199A4 (en) | Anti-ox40 antibodies and methods of using the same | |
| EP2760452A4 (en) | Methods of treating cancer | |
| EP2734234A4 (en) | Anti-cxcr4 antibodies and methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| HK1201843A1 (en) | Anti-polyubiquitin antibodies and methods of use | |
| HK1202877A1 (en) | Anti-cd98 antibodies and methods of use thereof cd98 | |
| HK1202240A1 (en) | Methods of treating cancer | |
| HK1201855A1 (en) | Antibodies and methods of treating cancer | |
| EP2731429A4 (en) | Compounds, methods of making, and methods of use | |
| HK1201537A1 (en) | Anti-kdr antibodies and methods of use -kdr | |
| EP2709999A4 (en) | Quinazoline-7-ether compounds and methods of use | |
| HK1199040A1 (en) | Use of antibody | |
| HK1190094A1 (en) | Anti-alpha-v integrin antibody for the treatment of prostate cancer --v | |
| HK1184173A1 (en) | Anti-kdr antibodies and methods of use -kdr | |
| IL232266A0 (en) | Methods of treating cancer |